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Summary The effect of administering the thiol modulating agent buthionine sulfoximine (BSO) in conjunc-
tion with alkylating chemotherapy was investigated in vivo in the mouse KHT sarcomas and bone marrow
stem cells. Tumour response to treatment was assessed by an in vivo to in vitro excision assay and bone
marrow survival was determined in vitro by CFU-GM. Glutathione (GSH) depletion and recovery kinetics were
determined at various times after treatment using high performance liquid chromatography (HPLC) techni-
ques. Following a single 2.5 mmol kg-' dose of BSO, tumour GSH reached a nadir of -40% of control
12-16 h after treatment. Bone marrow GSH was depeleted to -45% of control 4-8 h after treatment but
recovered to normal by 16 h. When a range ofdoses of CCNU, mitomycin C, cyclophosphamide or melphalan
(MEL) were given 16 h after mice were exposed to a 2.5 mmol kg-' dose of BSO, only the antitumour efficacy
of MEL was effectively enhanced (by a factor of -1.4). This BSO-MEL combination appeared to be selective
for the tumour as the bone marrow toxicity was not increased beyond that seen for MEL alone. Since
increasing the administered dose of BSO neither increased the extent of thiol depletion in the tumour nor
enhanced the antitumour efficacy of MEL, three other protocols for delivering the thiol depletor were
explored. BSO was given either as multiple 2.5 mmol kg-' doses administered at 6 or 16 h intervals or
continuously at a concentration of 30 mM supplied in the animals' drinking water. Both multi-dose BSO
pretreatments were found to increase both the antitumour efficacy and normal tissue toxicity of MEL such
that no advantage compared to the single dose combination was achieved. In contrast, maintaining the thiol
depletor in the drinking water led to an -1.7-fold increase in the antitumour efficacy of MEL without any
corresponding increase in bone marrow stem cell toxicity. For the various pretreatment strategies it was
possible, in all cases, to account for the presence or absence of a net therapeutic benefit on the basis of the
tumour and bone marrow GSH depletion and recovery kinetics.
Glutathione (GSH) has been shown to play a critical role in
the protection of cells against a variety of cytotoxic insults
(Arrick & Nathan, 1984). Of potential importance to cancer
therapists is the observation that tumour cells, particularly
those of human origin, have been found to contain very high
levels of GSH (Allalunis-Turner et al., 1988; Biaglow et al.,
1983; Mitchell et al., 1989) which suggests that GSH may be
a key factor limiting the therapeutic efficacy of cancer treat-
ment. This view is supported by a number of reports which
have shown that resistance to chemotherapeutic agents may
be due to elevated cellular GSH concentrations (Hamilton et
al., 1985; Lee et al., 1991; 1989; Suzukake et al., 1982;
Richardson & Siemann, 1992). Consequently there has been
considerable interest in developing approaches to overcoming
such thiol mediated therapy resistance. Although a number
of agents affect the cellular GSH content, most suffer from
non-specificity (Meister, 1983). However, the development of
L-Buthionine sulfoximine (BSO), an agent which has little
pharmacological activity other than the specific inhibition of
gamma-glutamylcysteine synthetase (Meister, 1983), has over-
come many of the previous difficulties associated with other
GSH depleting agents.
The potential of BSO as an adjuvant to conventional
chemotherapy is supported by a number of recent in vitro
and in vivo investigations which have shown that (i) depletion
of cellular GSH by BSO can increase the cytotoxicity of a
variety of anticancer drugs (Hamilton et al., 1985; Kramer et
al., 1987; 1989; Lee et al., 1989; 1991; Ono et al., 1986;
Ozols, 1985; Ozols et al., 1987; Tsutsui et al., 1986; Mitchell
et al., 1989; Kramer et al., 1989), and (ii) thiol mediated
resistance can be overcome by depletion of cellular GSH
prior to drug expsoure (Hamilton et al., 1985; Crook et al.,
1986; Ozols, 1985; Richardson & Siemann, 1992). Due to
these promising developments, there has been growing
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interest in the use of BSO as a chemosensitiser in cancer
chemotherapy. Indeed BSO is currently undergoing Phase I
clinical trial evaluation.
An important aspect of any combined modality approach
is the assessment of potential enhancement of toxicity in
critical normal tissue target organs. Since GSH also plays a
protective role in normal tissues and thiols in tumours and
normal tissues may be depleted at different rates and to
different extents after treatment with BSO (Lee et al., 1987;
Minchinton et al., 1984; Kramer et al., 1989), it is essential to
establish the conditions leading to optimal thiol manipula-
tions in tumour vs normal tissue. In particular it is important
to determine the conditions under which BSO and anticancer
drug combinations may lead to optimal antitumour treat-
ment efficacy and maximal therapeutic gain.
In the present study we initially compared the ability of
BSO to potentiate the antitumour efficacy of four conven-
tional alkylating chemotherapeutic agents (CCNU, mito-
mycin C, cyclophosphamide, melphalan). Since BSO was
found to be most effective at increasing the tumour cell kill
of melphalan (MEL) treatments, this agent was chosen for
subsequent investigations aimed at comparing the effective-
ness of different BSO treatment strategies when used in com-
bination with alkylating chemotherapy. For each treatment
schedule, we assessed in both the tumour and bone marrow,
(i) the kinetics of GSH depletion by BSO, and (ii) the effect
of BSO-MEL combination on clonogenic cell survival. On
the basis of these investigations we then determined whether
a given treatment strategy resulted in a therapeutic benefit.
Methods and materials
Animals and tumour transplantation
All experiments were performed with 8-12 week old female
C3H/HeJ mice obtained from Jackson Laboratories, Bar
Harbor, ME. The KHT sarcoma was used in all tumour
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response experiments and was maintained and passaged as
previously described (Thomson & Rauth, 1974). KHT cells
(2 x 105) were transplanted into the gastrocnemius muscle of
the hind limbs. After 10 days, when the tumours had grown
to a weight of 0.5-0.7 g, the mice were allocated randomly
into various groups and treated or kept as controls.
Drug administration
Buthionine sulfoximine (L-BSO) was dissolved in (i) phos-
phate buffered saline (PBS) solution, pH 7.4, and injected in
a volume of 0.01mlg` body weight or (ii) the animals'
drinking water at a concentration of 30 mM. CCNU (1-(2-
chloroethyl)-3-cyclohexyl-1-nitrosourea) was dissolved in
absolute ethanol and then, immediately prior to injection,
was further diluted with hydroxypropyl methylcellulose to
yield a final concentration of 1 mg ml'. The chemothera-
peutic agents mitomycin C (MIT C) and cyclophosphamide
(CP) were dissolved in saline to yield final concentrations of
1 and 10 mgml-' respectively. Melphalan (MEL) was dis-
solved in 10% acid alcohol and subsequently diluted with
PBS to a concentration of 0.5 or 1.0 mg ml-' just prior to
drug administration. All chemotherapeutic agents, as well as
BSO, were administered intraperitoneally according to body
weight of the mouse.
ium hydroxide. The effluent was monitored for fluorescence
with 340 nm excitation and emission at >410 nm. Quantifi-
cation was carried out on the basis of peak height with
reference to a calibration curve produced with authentic
GSH standards (Sigma Chemical).
Clonogenic tumour cell survival assay
Clonogenic cell survival was studied using an in vivo to in
vitro excision assay as previously described (Thomson &
Rauth, 1974). Briefly, KHT sarcoma cell survival was assay-
ed 24 h after treatment. Mice were killed by cervical disloca-
tion, their tumours excised, and a single cell suspension
prepared by a combined mechanical and enzymatic (2.5%
trypsin + DNase) procedure. The cells were counted using a
hemocytometer, diluted and mixed with 104 lethally irradi-
ated tumour cells in 0.2% agar containing alpha-minimum
essential medium supplemented with 10% FCS and plated
into 24 well dishes. After a 2 week incubation at 37°C, the
number of colonies formed was counted with the aid of a
dissecting microscope. Tumour cell survival after treatment
was calculated as the ratio of the treated to untreated cell
plating efficiencies. The in vitro plating efficiency of cells
derived from KHT tumours was typically 10 to 20%.
Sample preparationfor highperformance liquid
chromatography (HPLC)
Mice were sacrificed at various times following single or
multiple dose L-BSO treatments (2.5 mmol kg-'). Organs
and tumours were removed and stored for analysis at liquid
nitrogen temperature as previously described (Lee et al.,
1987). Briefly, organs and tumour samples were removed,
washed rapidly in 10mM 5-sulfosalicylic acid (SSA)/EDTA
(5 mM), and dried on tissue paper. Tissue samples were then
frozen immediately in liquid nitrogen and stored at -70°C
until analysis. To obtain bone marrow cells, the femurs from
tumour- and non-tumour-bearing mice were removed and the
marrow harvested using 0.5 ml alpha-minimum essential
medium supplemented with 10% foetal calf serum per femur.
Marrows of animals from the same treated group were pool-
ed and a single cell suspension was obtained. Appropriate
dilutions were made, Zapoglobin II (Coulter) used for lysis of
RBCs, and nucleated cells were then counted using a Coulter
Counter. Aliquots of the original suspension were used to
obtain 1 x 107 marrow cells, which were centrifuged at
1000 r.p.m. for 5 min. The resultant pellet was resuspended in
excess 3% glacial acetic acid to lyse unnucleated cells and
centrifuged at 1000 r.p.m. for 5 min. This resultant pellet was
stored at -70°C until analysis.
Preparation of frozen tissues and bone marrow cells for
analysis by HPLC were as prevously described (Lee et al.,
1987). Briefly, tissues were homogenised with 20 vol (w/v) of
20 mM SSA. Bone marrow cells were homogenised with
210 1l SSA. Tissue and bone marrow cell homogenates were
then centrifuged for 2 min in an Eppendorf microcentrifuge.
GSH contained in the supernatant was derivatised using the
fluorescent reagent monobromobimane (50 mM, mBBr, Thio-
lyte TM from Calbiochem). Aliquots of the supernatant
(180,l) were placed into test tubes containing 2gl of
mBBR + 12pl N-ethylmorphiline (NEM) and the sample
immediately vortexed and stored in the dark at 4°C until
analysis.
HPLC analysis
The pair-ion HPLC technique used to analyse GSH in the
present experiments has been previously described in detail
(Lee et al., 1987; Lee et al., 1989). Briefly, separation of GSH
was carried out on Waters Radial-PAK reversed-phase bond-
ed octadecylsilane (C18) cartridge columns (8 mm, I.D., 5ILm
diameter spherical particles). Isocratic elution was carried out
with a mobile phase of 23% acetonitrile in 40mM ammonium
phosphate buffer, pH 7.2, containing 5 mM tetraethylammon-
Bone marrow survival assay
The ability of bone marrow to form colonies was assessed by
the CFU-GM assay (Bradley & Metcalf, 1966). Mice were
sacrificed 24 h following treatment, femurs excised, bone
marrow harvested and nucleated cells counted on a Coulter
Counter. Appropriate dilutions were made and cells were
plated with 64% methylcellulose, 20% FCS, and 10% giant
tumour cell colony stimulating factor into 35 mm dishes.
After 7 days the colonies were counted on an inverted phase
microscope. Survival was determined from the ratio of the
treated to untreated cell plating efficiencies.
Results
Previous studies in our laboratories had already established
considerable information on GSH depletion and recovery
kinetics in a variety of tumours and normal tissues (Lee et
al., 1987). Since the aim of the present investigation was to
determined whether the inclusion of BSO in a chemothera-
peutic agent protocol could yield a therapeutic gain, initial
studies focused on comparing GSH depletion and recovery
kinetics in the KHT sarcoma and the bone marrow. Follow-
ing a single dose of 2.5 mmol kg-' BSO, the GSH contents
of the bone marrow and the KHT sarcomas were depleted in
a time dependent manner (Figure 1). In the bone marrow,
GSH levels decreased with time and reached a nadir of 45%
of untreated control between 4 and 8 h. This was followed by
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Figure 1 GSH in the KHT sarcoma (X) and bone marrow (-)
at various times after treatment with a single dose of
2.5mmolkg-' BSO. Data shown are the mean±s.e. of three
experiments.
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a rapid recovery in cellular thiol levels beyond the untreated
control value by 12 h. The nature of this apparent GSH
overshoot is unclear; although it has been observed in other
tissues following BSO treatment (Minchinton et al., 1984;
Lee et al., 1987). It is unlikely to be the consequence of a
dose priming phenomenon as was observed following CP
treatment (Adams et al., 1985) but rather may represent a
recovery of the GSH synthetic processes being interrupted by
the BSO treatment.
In contrast, the GSH levels in the KHT sarcoma appeared
to deplete and recover more slowly after BSO exposure than
did the bone marrow. GSH levels in the KHT sarcoma
reached a nadir of 37% of untreated controls between 12 and
16 h after treatment and then recovered to 80% of untreated
controls by 24 h. A similar time course of GSH depletion
and recovery previously was observed in other rodent
tumours (Minchinton et al., 1984; Lee et al., 1987) as well as
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human tumour xenografts (Siemann et al., unpublished
results).
On the basis of these GSH depletion kinetics initial thera-
peutic studies utilised a treatment in which BSO preceded a
variety of commonly used anticancer agents by 16 h. Figures
2 and 3 show the response of KHT sarcomas treated with
four alkylating agents (CCNU, MIT C, CP, MEL) either
alone or in combination with BSO. The results demonstrated
that the addition of BSO (i) had little effect on CCNU and
MIT C associated tumour cell killing (Figure 2a and 2b), (ii)
increased the efficacy of CP modestly (Figure 3a) and (iii)
enhanced the cell killing due to MEL in a dose modifying
manner (Figure 3b). From these data an enhancement ratio,
defined as the ratio of the slopes of the cell survival curves
obtained for MEL adminstered in the absence and presence
of BSO, was calculated to be -1.4.
In subsequent studies doses of BSO ranging from 0.25 to
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Figure 2 Clonogenic cell survival in KHT sarcomas 24 h after treatment with a range of doses of a, CCNU and b mitomycin C.
The chemotherapeutic agents were given either alone (open symbols) or 16 h after a 2.5 mmol kg-' dose of BSO (closed symbols).
The results are the mean±s.e. of three or four experiments.
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Figure 3 Clonogenic cell survival in KHT sarcomas 24 h after treatment with a range of doses of a, cyclophosphamide and b,
MEL. Treatments as in Figure 2.
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7.5 mmol kg-' were administered to tumour-bearing mice
16 h prior to a fixed 7.5 mg kg-' dose of MEL. For each
dose combination, the extent of GSH depletion as well as
enhancement of treatment efficacy were determined (Figure
4). The results indicated that BSO doses greater than 2 mmol
kg'- were required to observe a significant enhancement in
tumour cell killing as compared to that achieved for MEL
alone (Figure 4b). Such doses of BSO led to GSH levels
which were approximately 40% of control at the time of
MEL exposure (Figure 4a). Interestingly, increasing the dose
of BSO from 2.5 to 7.5 mmol kg-' did not lead to greater
GSH depletion in the tumour nor further enhancements of
the drug-induced cell kill.
The findings of Figure 4 suggested that, if the tumour
GSH levels could be further reduced, the antitumour efficacy
of MEL might be increased. Consequently, a number of
different BSO administration protocols were investigated.
Based on the single BSO dose tumour GSH depletion studies
(Figure 1), two multiple BSO exposure protocols were initi-
ated. In the first, BSO (2.5mmolkg-') was administered at
16 h intervals while the second, a 6 h time interval was
employed. The 16 h time interval was chosen since the single
dose studies (Figure 1) had shown that the GSH concentra-
tion 16 h after treatment was at a nadir in the KHT sarcoma.
The 6 h time interval was selected in an attempt to more
aggressively deplete the tumour GSH. For comparison to
these two multiple dosing protocols, other tumour-bearing
mice were continuously exposed to a 30 mM dose of BSO in
their drinking water. The GSH-depletion and recovery
kinetics in the KHT sarcoma under these different BSO
treatment schedules are shown in Figure 5.
When BSO (2.5 mmol kg-') was given at 16 h intervals,
GSH depletion reached a value of -35% of untreated con-
trols after the second BSO dose (Figure 5a). Additional
exposures to BSO failed to lower the tumour GSH levels
further. Indeed the fluctuations in the GSH measurements at
later times suggest that as the number of BSO exposures
increased, tumour GSH levels might possibly be recovering
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Figure 4 Effect of BSO dose on a, tumour GSH depletion and b,
MEL activity enhancement. A range of BSO doses were given
16 h prior to GSH measurement or MEL treatment
(7.5 mg kg-'). Clonogenic cell survival was determined 24 h after
MEL exposure. Data shown are the mean ± s.e. of three
experiments.
Figure 5 GSH levels in tumours of mice treated with multiple
doses of BSO (2.5 mmol kg-') given at either a, 16 or b 6h
intervals. Also shown are the tumour GSH concentrations in
mice maintained on drinking water containing 30 mM BSO. Data
are the results of two experiments. Arrows indicate the time of
MEL treatment in subsequent cell survival studies.
more rapidly. In the second multi-dose BSO protocol, KHT
sarcoma-bearing mice were treated with 2.5mmolkg-' BSO
doses at 6h intervals. With this treatment regimen the
tumour GSH levels were depleted to -10% of control after
five drug treatments (Figure Sb). Additional treatments did
not further reduce the GSH levels. Finally, a steady state
GSH level of - 12% could also be maintained in KHT
tumours when the mice were exposed to a 30 mM concentra-
tion of BSO in their drinking water (Figure 5c).
In concert with the GSH measurements made on KHT
tumours, GSH levels in the bone marrow of mice undergoing
the various BSO treatment regimen also were determined
(Figure 6). For the two multi-dose schedules (Figures 6a and
6b) the results showed rapid GSH recovery in the bone
marrow after the initial BSO exposures. However, in time,
GSH recovery between doses decreased in this normal tissue
until almost no recovery was seen. In contrast to the multi-
dose treatments, maintaining 30 mM BSO in the animals'
drinking water only reduced the bone marrow GSH by about
10%.
The impact of different BSO pretreatment regimes on the
response of KHT sarcomas and bone marrow are illustrated
in Figures 7 and 8, respectively. In these studies a range of
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Figure 6 Bone marrow GSH in mice treated with various BSO
pretreatment regimen as described in Figure 5.
doses of MEL was administered at the following times: (i)
16 h after a single 2.5 mmol kg-' dose of BSO, (ii) 8 h after
the fourth 2.5 mmol kg-' BSO dose in the 16 h interval
treatment protocol, (iii) 8 h after the fifth 2.5 mmol kg-' BSO
dose in the 6 h interval treatment protocol, and (iv) 96 h after
the start of the administration of 30 mM BSO in the animals'
drinking water. In all cases the MEL administration was
chosen to concur with maximal and/or steady state tumour
GSH depletion (Figure 5).
The effect of the various BSO pretreatment regimens on
the response of KHT sarcomas to MEL are illustrated in
Figure 7. The data show that all BSO pretreatments led to
increased MEL-induced cell killing, with the extent of the
enhancement varying according to the level of GSH deple-
tion achieved. For example, single dose and 16 h interval
BSO pretreatment strategies both led to -65% reductions in
tumour GSH (Figures 1 and 5) and concurrent 1.3-1.4-fold
enhancements in the antitumour efficacy of MEL (Figures 7a
and 8b). Administering BSO, either at 6 h intervals or at a
constant level in the drinking water, reduced the tumour
GSH levels by -90% (Figure 5) and enhanced the cell
killing of MEL -1.7-fold (Figures 7c and 7d).
As was seen in the tumour studies, the degree to which the
MEL-induced bone marrow toxicity was enhanced by BSO
pretreatment, was found to be related to the extent of the
GSH depletion at the time of chemotherapeutic agent expo-
sure (Figure 8). For example, administering MEL 16 h after
a single 2.5 mmol kg-' dose of BSO, i.e. at a time when the
bone marrow GSH had returned to normal (Figures 1 and
6a), resulted in bone marrow toxicity, as assessed by CFU-
GM survival, similar to that seen for MEL alone without
BSO pretreatment (Figure 8a). Unlike the single BSO dose
studies, both multi-dose BSO pretreatment schedules led to
(i) a 70-80% GSH depletion in the bone marrow at the time
of MEL treatment (Figures 6a and 6b) and (ii) some direct
toxicity to the cells as well as an -1.3-fold increase in bone
marrow stem cell toxicity when combined with MEL (Figures
8b and 8c). In contrast, mice kept on drinking water contain-
ing 30 mM BSO, showed only a 10% reduction in bone
marrow GSH (Figure 6c) and no increase in CFU-GM tox-
icity as compared to MEL alone (Figure 8d).
Discussion
The central aims of the present studies were to investigate
whether the specific thiol depletor BSO could be used to (i)
improve the tumour response and (ii) yield a therapeutic
benefit when combined with conventional alkylating chemo-
therapeutic agents. Alkylating agents represent a class of
anticancer drugs which demonstrate considerable cytotoxic
activity against a variety of tumour types (Farmer, 1987).
Unfortunately, relapse and development of resistance are
common. Resistance to alkylating agents occurs via a
number of mechanisms, including decreased drug accumula-
tion, increased repair of drug-induced lesions, and cellular
inactivation of the drug (Colvin et al., 1988).
One potentially important mechanism of alkylating drug
resistance may be the development of elevated intracellular
levels of GSH (Hosking et al., 1990). Indeed, increased GSH
contents have been associated with drug resistance in rodent
and human tumour cell lines. For example, results by Ozols
and others (Ozols, 1985; Hamilton et al., 1985; Suzukake et
al., 1982) showed a correlation between MEL cytotoxicity
and GSH levels both in drug resistant L1210 leukaemia and
in human ovarian cancer cell lines. More recently, Lee and
colleagues (Lee et al., 1991) used 21 tumour lines to demon-
strate a relationship between steady-state cellular GSH con-
tents and chemosensitivity to 4-hydroperoxycyclophospha-
mide.
Not only is there strong experimental evidence for the role
of GSH in at least some forms of drug resistance, but it has
been suggested that GSH might be an even greater determin-
ing factor when human tumours are treated with chemo-
therapy. This is because data are accumulating which
demonstrate that GSH contents in human tumours may be
higher than in rodent tumour models (Allalunis-Turner et al.,
1988; Lee et al., 1988; Morstyn et al., 1984; Mitchell et al.,
1989).
In order to overcome this form of drug resistance, it has
been suggested to attempt to modulate GSH levels in patients
undergoing cancer treatment. One possible tactic, currently
being explored in Phase I clinical studies, is the use of the
agent BSO, a relatively non-toxic compound which depletes
cells of GSH by inhibiting its synthesis (Meister, 1983). The
potential for this approach is supported by a large number of
preclinical investigations which have shown that depletion of
cellular GSH by BSO can increase the cytotoxicity of a
variety of anticancer drugs both in vitro and in vivo (Hamil-
ton et al., 1985; Ozols et al., 1987; Ono et al., 1986; Richard-
son & Siemann, 1992; Lee et al., 1989; Tsutsui et al., 1986;
Mitchell et al., 1989; Kramer et al., 1989).
In agreement with other reports (Minchinton et al., 1984;
Lee et al., 1987; Kramer et al., 1987) the findings of the
present studies indicate that GSH contents can be effectively
reduced with BSO in normal and tumour tissues. In addition,
as had also been shown previously (Minchinton et al., 1984;
Lee et al., 1987; Kramer et al., 1987), considerable diversity
was seen in the rate of GSH depletion and -recovery in
normal and tumour tissues following the administration of a
single dose of 2.5 mmol kg-' BSO (Figure 1). In particular,
after treatment with this dose, the GSH levels in the tumour
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Figure 7 Clonogenic cell survival in KHT sarcomas treated with a range of MEL doses following pretreatment with (closed
symbols) or without (open symbols) BSO. Mice were given either a, a single 2.5 mmol kg-' dose of BSO 16 h before MEL, b, four
doses of BSO (2.5 mmol kg-') at 6 h intervals prior to MEL, c, four doses of BSO (2.5 mmol kg-') at 6 h intervals prior to MEL,
or d, MEL 4 days after placing the mice on a water supply containing 30 mM BSO. The dashed curves show the response to MEL
alone (redrawn from a). Data shown are the mean ± s.e. of three experiments.
reached a nadir at a time when the bone marrow GSH levels
had recovered to normal or above control values (Figure 1).
The focus of the present study was to determine whether
such information on thiol depletion and recovery kinetics in
tumours and critical normal tissues, such as the bone mar-
row, could be translated into a therapeutic benefit when BSO
is used in combination with conventional anticancer agents.
Our findings showed that, of the four chemotherapeutic
agents investigated, only the activity of MEL could be
enhanced significantly by pretreatment with a 2.5 mmol kg-'
dose of BSO (Figures 2 and 3). For this anticancer agent,
when the tumours were treated at the time that the tumour
GSH was at a nadir, an -1.4-fold enhancement in tumour
cell killing could be achieved (Figure 3b). Increasing the
administered dose of BSO beyond 2.5 mmol kg-' did not
however lead to further increases in the level of MEL-
induced tumour cell killing (Figure 4b). This latter observa-
tion most likely was a consequence of the failure of the larger
single doses of BSO to decrease the tumour GSH concentra-
tions below those achieved with 2.5 mmol kg-' (Figure 4a).
In an attempt to decrease further the tumour thiol levels
and hence increase the tumour cell kill, different protocols
for administering BSO prior to anticancer agent exposure
were investigated. In agreement with our previous report
(Lee et al., 1987), the present results (Figures 1, 5 and 6)
indicated that: (i) different tissues can vary significantly in the
rates of GSH depletion and recovery, and (ii) the extent of
thiol depletion and rate of recovery may change when multi-
ple rather than single dose BSO treatments are utilised. Most
disturbingly, in the multi-dose experiments it appeared that
with each additional dose of BSO, GSH-recovery became
more significant in the KHT sarcoma and less effective in the
bone marrow (Figures 5 and 6). Indeed multiple BSO doses
given at 16 h intervals (i.e. the time of the nadir of the
tumour GSH after a single dose), failed to reduce the tumour
GSH level below that achievable with a single dose (Figure
5a vs 1). In contrast, this timing, which after a single dose
allowed full recovery of the GSH in the bone marrow, when
used in multiple dosings, led to a rapid decline in the marrow
thiol values (Figure 6a vs 1). Administering BSO doses at
even shorter time intervals (6 h), did reduce GSH levels
beyond those obtained with single doses (Figure 6b) but also
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Figure 8 Bone marrow stem cell survival in mice treated with
pretreatments (solid symbols) as described in Figure 7.
led to more extensive thiol reductions in the bone marrow
(Figure 6b). Thus attempts at preferential tumour GSH
depletion through multiple BSO exposures showed that selec-
tion through differential recovery rates was not entirely suc-
cessful. Perhaps the present changes in GSH kinetics in
tissues are a consequence of differences in steady states of
GSH synthesis as have been shown to influence the
therapeutic response of different ovarian tumour cell lines
(Lee et al., 1989).
Ultimately, for the modulation of systemic chemotherapy
by an adjuvant to be of any therapeutic value, it needs to be
demonstrated that enhancements similar to, or greater than,
those seen in the tumour do not occur in critical normal
tissues. To address this issue for the combination of BSO and
MEL, we evaluated this treatment strategy in terms of possi-
ble increased bone marrow toxicity. When single doses of
BSO were used in conjuntion with MEL, little enhancement
of MEL-induced bone marrow toxicity was seen (Figure 8a).
This finding was most likely due to the fact that at the time
when the chemotherapeutic agent was administered, the bone
marrow GSH had recovered to normal levels (Figure 1).
These results are in agreement with those of other investi-
gators who have shown that the potentiation of bone marrow
toxicity is minimal when BSO is combined with adjuvant
MEL alone (open symbols) or MEL following various BSO
chemotherapy (Ono et al., 1986; Ozols et al., 1987; Tsutsui et
al., 1986; Russo et al., 1986; Mitchell et al., 1989). In our
laboratories we have further observed that a single 2.5 mmol
kg-' dose of BSO had little effect on either the acute animal
lethality of doxorubicin (Lee et al., 1987) or the lung toxicity
of cyclophosphamide (Allalunis-Turner et al., unpublished
results). Given the observed increase in antitumour effect in
the absence of enhanced bone marrow toxicity, it could be
argued that our single dose BSO-MEL combination had
resulted in an improved therapeutic index.
To determine whether a therapeutic gain could be achieved
when multiple BSO exposures were combined with MEL,
tumour response and bone marrow toxicity under these treat-
ment conditions were assessed. Administering BSO four
times prior to MEL, either at 16 or 6 h intervals, increased
MEL antitumour efficacy -1.3- and -1.7-fold respectively
(Figure 7b and 6c). This compares to an ER of
- 1.4
observed when BSO was given as a single exposure 16 h prior
to MEL (Figure 1). However, unlike the single dose of BSO
pretreatment results, when administered as multiple expo-
sures, not only did BSO appear to yield some stem cell
toxicity on its own, but in addition led to enhancement of the
marrow toxicity due to MEL (Figure 8b and 8c vs 8a). Thus
administering BSO doses repeatedly at 16 h time intervals, to
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deplete tumour GSH prior to MEL treatment, led to little or
no therapeutic gain. The 6 h pretreatment schedule did con-
fer a large enhancement in the antitumour activity of MEL.
However, due to the associated increase in bone marrow
toxicity, the resultant therapeutic benefit was not larger than
that seen with the single dose BSO-MEL combination.
The failure of the multi-dose BSO pretreatments to yield a
significant therapeutic benefit most likely was related directly
to the unfavourable bone marrow and tumour tissue GSH
depletion and recovery kinetics resulting from these treat-
ments strategies (see Discussion above). In contrast, when
KHT sarcoma-bearing mice were kept on drinking water
containing 30 mM BSO, the GSH levels in the tumours fell to
10-15% of control (Figure 5c) whereas those in the bone
marrow were reduced by only -10% (Figure 6c). When
these animals were treated with MEL 4 days after starting
the BSO treatment, the antitumour efficacy of this chemo-
therapeutic agent was found to be enhanced (-1.7-fold;
Figure 7d) but the bone marrow toxicity was not increased
(Figure 8d). Consequently, the drinking water treatment
regimen led to the largest therapeutic gain in the present
series of preclinical investigations using thiol depletion in
conjunction with alkylating chemotherapy. This finding is
comparable to enhancements seen in preclinical tumour
models utilising a similar GSH depletion protocol in com-
bination with hypoxic cell sensitisers and fractionated radia-
tion treatments (Kramer et al., 1989). These results suggest
that chronic depletion of tumour GSH by prolonged BSO
pretreatment ought to be considered in clinical trials of GSH
modulation.
In conclusion, the evaluation of combinations of BSO with
chemotherapy is currently a subject of extensive research.
The present study has shown that it is possible in a model
system to achieve a therapeutic benefit when BSO is com-
bined with MEL if dose-timing and dose-sequencing are
carefully evaluated. The BSO-MEL combination may be of
particular interest since MEL remains one of the most
effective single agents in the treatment of ovarian cancer. Our
findings further suggest that, in clinical investigations aimed
at modifying chemotherapeutic agent efficacy through thiol
manipulations, there is a need to acquire detailed knowledge
of the GSH depletion and recovery kinetics in critical normal
tissues as well as tumours. No single normal tissue is likely to
be representative of all others. Hence the best strategy may
be to monitor the GSH content of a known dose-limiting
tissue. Measurements of tumour GSH may be particularly
critical and problematic given the difficulties associated with
determining tumour GSH from biopsy specimens (Allalunis-
Turner et al., 1988; Mitchell et al., 1989). Specifically, the
regional variations in GSH measurements described for multi-
ple biopsy samples taken from the same tumour (Allalunis-
Turner et al., 1988) need to be considered in the interpretation
of clinical studies utilising thiol modulating agents. Despite
these reservations, the experimental preclinical models
strongly suggest that manipulation of tumour GSH may
benefit selected patients.
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